{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:52Z","timestamp":1793647672377,"version":"4.5.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s15010-026-02893-w","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:26:31Z","timestamp":1786631191000},"page":"2633-2641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Redefining susceptibility in practice : clinical and resistance outcomes of the EUCAST \u2018I\u2019 category for wild-type Pseudomonas aeruginosa"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2152-5626","authenticated-orcid":false,"given":"Melike","family":"T\u00f6r\u00fcyenler Co\u015fkunp\u0131nar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7613-2398","authenticated-orcid":false,"given":"Elif M.","family":"Sar\u0131cao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2467-6625","authenticated-orcid":false,"given":"G\u00fcle","family":"\u00c7\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-9148","authenticated-orcid":false,"given":"\u0130rem","family":"Akdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-7716","authenticated-orcid":false,"given":"Ezgi","family":"G\u00fclten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6538-5602","authenticated-orcid":false,"given":"Pelin","family":"\u00c7akmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-055X","authenticated-orcid":false,"given":"Alpay","family":"Azap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2893_CR1","doi-asserted-by":"publisher","unstructured":"Diggle SP, Whiteley M, Corrigendum. Microbe profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat. Microbiol (Reading). 2020;166(1):30-33. https:\/\/doi.org\/10.1099\/mic.0.000860","DOI":"10.1099\/mic.0.000860"},{"key":"2893_CR2","unstructured":"Kahlmeter G. Redefining susceptibility testing categories S, I and R 2019 [Available from: https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/definition-of-s-i-and-r\/"},{"issue":"12","key":"2893_CR3","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.cmi.2024.07.010","volume":"30","author":"A Aupaix","year":"2024","unstructured":"Aupaix A, Mzougui S, Soleimani R. Impact of susceptible, increased exposure, a new definition of the former intermediate susceptibility category, introduced by the European Committee for Antimicrobial Susceptibility Testing on antimicrobial susceptibility testing evaluation. Clin Microbiol Infect. 2024;30(12):1494\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2893_CR4","doi-asserted-by":"publisher","first-page":"e0027621","DOI":"10.1128\/jcm.00276-21","volume":"60","author":"CG Giske","year":"2022","unstructured":"Giske CG, Turnidge J, Canton R, Kahlmeter G, Committee ES. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol. 2022;60(3):e0027621.","journal-title":"J Clin Microbiol"},{"issue":"Suppl 3","key":"2893_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.37201\/req\/s03.18.2022","volume":"35","author":"SG Nabal Diaz","year":"2022","unstructured":"Nabal Diaz SG, Algara Robles O, Garcia-Lechuz Moya JM. New definitions of susceptibility categories EUCAST 2019: clinic application. Rev Esp Quimioter. 2022;35(Suppl 3):84\u20138.","journal-title":"Rev Esp Quimioter"},{"issue":"12","key":"2893_CR6","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.cmi.2020.07.025","volume":"26","author":"S Meylan","year":"2020","unstructured":"Meylan S, Guery B. In the name of common sense: EUCAST breakpoints and potential pitfalls. Clin Microbiol Infect. 2020;26(12):1593\u20134.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2893_CR7","doi-asserted-by":"publisher","first-page":"dlac099","DOI":"10.1093\/jacamr\/dlac099","volume":"4","author":"C Ourghanlian","year":"2022","unstructured":"Ourghanlian C, Fihman V, Morel A, Lafont C, Galy A, Calimouttoupoulle E, et al. Overly broad-spectrum antibiotic treatment of wild-type Pseudomonas aeruginosa infections in relation to the EUCAST new definition of susceptibility testing categories, a retrospective multicentre cohort study. JAC Antimicrob Resist. 2022;4(5):dlac099.","journal-title":"JAC Antimicrob Resist"},{"issue":"4","key":"2893_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cmi.2021.03.034","volume":"28","author":"A Munting","year":"2022","unstructured":"Munting A, Regina J, Damas J, Lhopitallier L, Kritikos A, Guery B, et al. Impact of 2020 EUCAST criteria on meropenem prescription for the treatment of Pseudomonas aeruginosa infections: an observational study in a university hospital. Clin Microbiol Infect. 2022;28(4):558\u201363.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"2893_CR9","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/cid\/ciz668","volume":"70","author":"T Babich","year":"2020","unstructured":"Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, et al. Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection: a multisite retrospective study. Clin Infect Dis. 2020;70(11):2270\u201380.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2893_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13613-017-0296-z","volume":"7","author":"E Yusuf","year":"2017","unstructured":"Yusuf E, Van Herendael B, Verbrugghe W, Ieven M, Goovaerts E, Bergs K, et al. Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration. Ann Intensive Care. 2017;7(1):72.","journal-title":"Ann Intensive Care"},{"issue":"12","key":"2893_CR11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","volume":"67","author":"SS Kadri","year":"2018","unstructured":"Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803\u201314.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2893_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13756-022-01203-x","volume":"11","author":"A Munting","year":"2022","unstructured":"Munting A, Damas J, Viala B, Prod\u2019hom G, Guery B, Senn L. Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital. Antimicrob Resist Infect Control. 2022;11(1):165.","journal-title":"Antimicrob Resist Infect Control"},{"key":"2893_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2025.04.016","volume":"161","author":"P Duch-Llorach","year":"2025","unstructured":"Duch-Llorach P, Simonetti AF, Figueras-Roig A, Rivera A, de Gamarra-Martinez EF, Gras-Martin L, et al. Successful implementation of a bundle to prevent increased excessive-spectrum antimicrobial use under new EUCAST susceptibility definitions: a quasi-experimental study in a tertiary hospital. J Hosp Infect. 2025;161:1\u20139.","journal-title":"J Hosp Infect"},{"issue":"7","key":"2893_CR14","doi-asserted-by":"publisher","first-page":"105130","DOI":"10.1016\/j.idnow.2025.105130","volume":"55","author":"C About","year":"2025","unstructured":"About C, Meyer F, Simon M, Jeanbert E, Demore B, Charmillon A. Modification of reported antibiotic susceptibility testing according to the EUCAST recommendations: evaluation of the appropriateness of antibiotic prescriptions in a university hospital. Infect Dis Now. 2025;55(7):105130.","journal-title":"Infect Dis Now"},{"issue":"8","key":"2893_CR15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cmi.2019.04.005","volume":"25","author":"A Rojas","year":"2019","unstructured":"Rojas A, Palacios-Baena ZR, Lopez-Cortes LE, Rodriguez-Bano J. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(8):964\u201370.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2893_CR16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/idr16050064","volume":"16","author":"C Pallotto","year":"2024","unstructured":"Pallotto C, Tommasi A, Svizzeretto E, Genga G, Gamboni G, Gidari A, et al. Bloodstream infections due to wild-type Pseudomonas aeruginosa: carbapenems and ceftazidime\/avibactam prescription rate and impact on outcomes. Infect Dis Rep. 2024;16(5):828\u201335.","journal-title":"Infect Dis Rep"},{"issue":"5","key":"2893_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/jac\/dkaf080","volume":"80","author":"DF Bavaro","year":"2025","unstructured":"Bavaro DF, Accurso G, Corcione S, Vena A, Schenone M, Diella L, et al. Antipseudomonal cephalosporins versus piperacillin\/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block? J Antimicrob Chemother. 2025;80(5):1342\u201353.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2893_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1186\/s40064-016-2438-4","volume":"5","author":"MA Barron","year":"2016","unstructured":"Barron MA, Richardson K, Jeffres M, McCollister B. Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites. Springerplus. 2016;5(1):755.","journal-title":"Springerplus"},{"issue":"12","key":"2893_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jiac.2018.08.001","volume":"24","author":"S Hirayama","year":"2018","unstructured":"Hirayama S, Yasui K, Murakami H, Kosugi T, Sakamoto M, Hanai Y, et al. A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa. J Infect Chemother. 2018;24(12):949\u201353.","journal-title":"J Infect Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02893-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:49:55Z","timestamp":1793645395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02893-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2893"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02893-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Ankara University Faculty of Medicine (approval number: \u013004-333-25; date: 02 May 2025). The requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}